Piper Sandler Upgrades Meta Platforms to Overweight, Raises Price Target to $215
Piper Sandler analyst Thomas Champion upgrades Meta Platforms (NASDAQ:META) from Neutral to Overweight and raises the price target from $136 to $215.
Piper Sandler Upgrades HomeStreet to Neutral
Piper Sandler analyst Matthew Clark upgrades HomeStreet (NASDAQ:HMST) from Underweight to Neutral.
OTR Global Upgrades Burlington Stores to Positive
OTR Global upgrades Burlington Stores (NYSE:BURL) from Mixed to Positive.
UBS Upgrades FinVolution Gr to Buy
UBS analyst Alex Ye upgrades FinVolution Gr (NYSE:FINV) from Neutral to Buy.
Hovde Group Upgrades Wintrust Finl to Outperform, Announces $108 Price Target
Hovde Group analyst Ben Gerlinger upgrades Wintrust Finl (NASDAQ:WTFC) from Market Perform to Outperform and announces $108 price target.
BMO Capital Upgrades Martinrea International to Outperform, Raises Price Target to C$15
BMO Capital analyst Peter Sklar upgrades Martinrea International (TSX:MRE) from Market Perform to Outperform and raises the price target from C$12 to C$15.
BMO Capital Upgrades Linamar to Outperform, Raises Price Target to C$80
BMO Capital analyst Peter Sklar upgrades Linamar (TSX:LNR) from Market Perform to Outperform and raises the price target from C$67 to C$80.
JP Morgan Upgrades Hubbell to Neutral, Announces $205 Price Target
JP Morgan analyst Stephen Tusa upgrades Hubbell (NYSE:HUBB) from Underweight to Neutral and announces $205 price target.
Needham Upgrades NeoGenomics to Buy, Announces $15 Price Target
Needham analyst Mike Matson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces $15 price target.
FibroGen Shares Gain As Analyst Creates Bullish Pitch On Pulmonary Fibrosis Opportunity
William Blair has upgraded FibroGen Inc (NASDAQ:FGEN) from Market Perform To Outperform, citing a deep dive opportunity for its wholly owned monoclonal…